Pluripotent stem cell lines available for use in clinical applications: A comprehensive overview

Over the last 25 years, there has been tremendous progress in human pluripotent stem cell (hPSC) technology and clinical trials testing hPSC-derived products. The development of these hPSC-derived products requires the selection of a suitable hPSC line as the starting material for product manufacturing. The bespoke development of an hPSC line for product development can require significant time and resources. Given the acceleration of clinical trials testing hPSC-derived products, there is a growing need for available clinically and commercially suitable "off-the-shelf" hPSC lines. We have identified 166 clinical hPSC lines that are currently available for licensing and distribution. This paper provides details regarding these lines that may assist developers in preliminary evaluation of lines for use in clinical development.